YOMI PHARMA

Yomi Pharma is a young biotech company exploiting the natural properties of sortilin protein to develop innovative therapeutic solutions. Our ambition is to develop and clinically validate therapeutic assets, particularly in oncology. Our first candidate is a "first-in-class" anti-EGFR peptide derived from sortilin that targets lung adenocarcinoma, after acquiring secondary mutations of EGFR and resistance to Tyrosine Kinases Inhibitors.